Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XENE - Xenon Pharmaceuticals Inc.


IEX Last Trade
40.12
0   0%

Share volume: 20,503
Last Updated: Tue 24 Dec 2024 03:31:02 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.45%

PREVIOUS CLOSE
CHG
CHG%

$40.12
-2.13
0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
15%
Profitability 8%
Dept financing 2%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
-1.83%
1 Month
-7.32%
3 Months
-2.57%
6 Months
3.26%
1 Year
-13.44%
2 Year
1.44%
Key data
Stock price
$40.12
P/E Ratio 
-18.63
DAY RANGE
$37.61 - $38.44
EPS 
-$2.50
52 WEEK RANGE
$36.84 - $50.99
52 WEEK CHANGE
-$13.44
MARKET CAP 
3.056 B
YIELD 
N/A
SHARES OUTSTANDING 
75.765 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.69
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$547,928
AVERAGE 30 VOLUME 
$422,759
Company detail
CEO: Ian C. Mortimer
Region: US
Website: xenon-pharma.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Xenon Pharmaceuticals Inc. engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy. XEN007, a central nervous system-acting calcium channel modulator, is in Phase II clinical trials.

Recent news